Low number of Covid cases now as India chose right vaccine: Serum CEO

In India, experts are deciding on mixing vaccines though it is allowed the world over, Poonawalla added

Adar Poonawalla, chief executive officer, Serum Institute of India
Adar Poonawalla, chief executive officer (CEO) of Serum Institute of India (Photo: PTI image)
Press Trust of India Pune
2 min read Last Updated : Apr 05 2022 | 12:06 AM IST

Serum Institute of India CEO Adar Poonawalla on Monday said the low number of COVID-19 cases at the moment was because the country chose the right vaccine.

Speaking to reporters on the sidelines of the 'Alternate Fuel Conclave', he said the fourth wave, if at all it occurs, will hopefully be mild.

Speaking on the booster dose, he said, "About the booster dose, we have appealed to the government, because everyone who needs to travel, needs the booster dose. They (government) are having internal discussions and a policy on booster dose may be announced soon."

All other countries are doing it and it was now time for India to have a look at it (booster dose), Poonawalla said, adding that the Centre had done a fantastic job by covering most of eligible adult population with two vaccine doses.

"Our vaccines have proven better that those in other countries. Look at US, and Europe, they have a lot of cases. We have fewer cases because we chose the right vaccines," he said.

Queried on whether the vaccines in their current form work on new coronavirus variants, he said they will work only if a booster dose is taken, as this will form protection from future variants.

In India, experts are deciding on mixing vaccines though it is allowed the world over, Poonawalla added.

The Pune-based SII manufactures Covishield vaccine.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusDelta variant of coronavirusOmicronCoronavirus TestsCoronavirus VaccineSerum Institute of India

First Published: Apr 04 2022 | 5:28 PM IST

Next Story